Citius Pharma Goes Commercial with LYMPHIR Launch, Faces Going Concern Doubt

Ticker: CTXR · Form: 10-K · Filed: Dec 23, 2025 · CIK: 1506251

Sentiment: mixed

Topics: Biopharmaceutical, Oncology, Drug Development, Going Concern, Commercial Launch, CTCL, Reverse Merger

Related Tickers: CTXR, CTOR

TL;DR

**CTXR just launched LYMPHIR, but the 'going concern' warning means it's a high-stakes bet on commercial success or bust.**

AI Summary

Citius Pharmaceuticals, Inc. (CTXR) launched LYMPHIR in December 2025 through its majority-owned subsidiary, Citius Oncology, marking its transition to a commercial company. The company reported a market value of voting and non-voting common equity held by non-affiliates of approximately $11,390,000 as of March 31, 2025, with 20,762,917 shares outstanding as of December 17, 2025. CTXR maintains a majority ownership of Citius Oncology at 77.9% as of December 17, 2025, following the August 2024 reverse merger. The company continues to develop late-stage product candidates including Mino-Lok for catheter-related bloodstream infections, Halo-Lido for hemorrhoids, and NoveCite for ARDS. Despite the commercial launch, the independent registered public accounting firm's report includes an explanatory paragraph stating substantial doubt about CTXR's ability to continue as a going concern, highlighting the critical need for additional funding and successful commercialization of LYMPHIR.

Why It Matters

Citius Pharmaceuticals' transition to a commercial entity with the LYMPHIR launch is a pivotal moment, potentially offering a new treatment option for CTCL patients and validating years of R&D. For investors, this marks a shift from pure development risk to commercial execution risk, but the 'going concern' warning signals significant financial instability. Employees face uncertainty given the company's funding challenges, while customers could benefit from a new therapy in a competitive oncology market. The success or failure of LYMPHIR will heavily influence CTXR's future and its ability to compete with larger pharmaceutical players.

Risk Assessment

Risk Level: high — The independent registered public accounting firm's report includes an explanatory paragraph stating 'substantial doubt about our ability to continue as a going concern,' indicating severe financial risk. The company also explicitly states it 'requires substantial additional funding, which may not be available on acceptable terms, or at all,' directly impacting its operational viability and commercialization efforts.

Analyst Insight

Investors should approach CTXR with extreme caution due to the 'going concern' warning and significant funding needs. While the LYMPHIR launch offers potential upside, the immediate focus should be on the company's ability to secure additional capital and demonstrate strong initial commercial traction for LYMPHIR to mitigate the high financial risk.

Financial Highlights

debt To Equity
N/A
revenue
$0
operating Margin
N/A
total Assets
N/A
total Debt
N/A
net Income
N/A
eps
N/A
gross Margin
N/A
cash Position
N/A
revenue Growth
N/A

Key Numbers

Key Players & Entities

FAQ

What is Citius Pharmaceuticals' primary business focus?

Citius Pharmaceuticals, Inc. focuses on developing and commercializing first-in-class critical care products, with an emphasis on oncology, anti-infectives in adjunct cancer care, and unique prescription products. Their strategy involves new formulations of previously approved drugs to reduce development risk.

When did Citius Pharmaceuticals launch its first commercial product, LYMPHIR?

Citius Pharmaceuticals, Inc. launched its first commercial product, LYMPHIR, in December 2025 through its majority-owned subsidiary, Citius Oncology, Inc. This marks the company's transition to a commercial entity.

What is the significance of the 'going concern' warning for Citius Pharmaceuticals?

The 'going concern' warning from Citius Pharmaceuticals' independent registered public accounting firm indicates substantial doubt about the company's ability to continue operations. This highlights a critical need for additional funding and successful commercialization efforts to sustain the business.

What other product candidates is Citius Pharmaceuticals developing?

Beyond LYMPHIR, Citius Pharmaceuticals is developing Mino-Lok, an antibiotic lock solution for catheter-related bloodstream infections; Halo-Lido, a topical formulation for hemorrhoids; and NoveCite, a mesenchymal stem cell therapy for acute respiratory disease syndrome (ARDS).

What was the market value of Citius Pharmaceuticals' common equity held by non-affiliates?

As of March 31, 2025, the aggregate market value of the voting and non-voting common equity held by non-affiliates of Citius Pharmaceuticals was approximately $11,390,000.

How much of Citius Oncology does Citius Pharmaceuticals own?

As of December 17, 2025, Citius Pharmaceuticals, Inc. owned approximately 77.9% of the outstanding shares of common stock of Citius Oncology, Inc., following the August 2024 reverse merger.

What is the primary risk associated with Citius Pharmaceuticals' dependence on LYMPHIR?

Both Citius Pharmaceuticals and Citius Oncology are heavily dependent on the launch and commercial success of LYMPHIR. Failure to achieve successful commercialization or maintain profitability from LYMPHIR could severely impact the company's financial viability and future operations.

What was the total number of Citius Pharmaceuticals' shares outstanding as of December 17, 2025?

As of December 17, 2025, Citius Pharmaceuticals, Inc. had 20,762,917 shares of common stock outstanding, all of one class with a $0.001 par value.

What is the purpose of the reverse merger involving Citius Oncology?

The August 2024 reverse merger with TenX Keane Acquisition resulted in SpinCo (now Citius Oncology Sub) surviving as a wholly-owned subsidiary of TenX, which was renamed Citius Oncology, Inc. (CTOR). This transaction made Citius Oncology a standalone publicly-traded company, with Citius Pharma retaining majority ownership.

What are the potential consequences if Citius Pharmaceuticals fails to secure additional funding?

If Citius Pharmaceuticals fails to obtain necessary capital on acceptable terms, it could be forced to delay, limit, reduce, or terminate its commercialization efforts and business operations. This could also lead to the Board of Directors pursuing a dissolution and liquidation of the company.

Risk Factors

Industry Context

Citius Pharmaceuticals operates in the biopharmaceutical sector, focusing on critical care products with a strategy of reformulating existing drugs to reduce development risk. The industry is characterized by high R&D costs, stringent regulatory hurdles, and significant competition from established players. Companies often seek to address unmet medical needs in areas like oncology and anti-infectives, aiming for intellectual property and regulatory exclusivity to gain market advantage.

Regulatory Implications

The company's success is heavily dependent on navigating complex regulatory pathways, particularly FDA approvals for its product candidates. Compliance with stringent manufacturing, marketing, and safety regulations is critical. The approval of LYMPHIR demonstrates regulatory success, but ongoing compliance and potential future approvals for Mino-Lok, Halo-Lido, and NoveCite remain key regulatory considerations.

What Investors Should Do

  1. Monitor LYMPHIR commercialization progress closely.
  2. Assess the company's ability to secure additional financing.
  3. Evaluate progress on late-stage product candidates (Mino-Lok, Halo-Lido, NoveCite).
  4. Analyze competitive landscape and market dynamics for LYMPHIR.

Key Dates

Glossary

Going Concern
A business's ability to continue operating for the foreseeable future without the threat of liquidation. (The auditor's report indicates substantial doubt about CTXR's ability to continue as a going concern, highlighting significant financial risks.)
Catheter-related bloodstream infections (CRBSIs)
Infections that occur when bacteria or other germs enter the bloodstream through a central venous catheter. (Mino-Lok is a product candidate developed by CTXR to treat these infections, addressing a significant unmet medical need.)
Mesenchymal stem cell therapy
A type of regenerative medicine that uses stem cells to treat diseases or injuries. (NoveCite, a product candidate for ARDS, utilizes this advanced therapeutic approach.)
Engineered IL-2 diphtheria toxin fusion protein
A type of therapeutic protein designed to target and kill specific cells, in this case, cancer cells. (LYMPHIR, CTXR's commercialized product, is based on this technology for treating CTCL.)
Cutaneous T-cell lymphoma (CTCL)
A rare type of non-Hodgkin lymphoma that affects the skin. (LYMPHIR is approved for the treatment of persistent or recurrent CTCL.)

Year-Over-Year Comparison

This filing marks a significant transition for Citius Pharmaceuticals as it has launched its first commercial product, LYMPHIR, in December 2025. While specific year-over-year financial comparisons for revenue and profitability are not yet available due to the recent commercialization and the reporting period, the company's strategic focus has shifted from pure development to commercial execution. A key risk factor highlighted in the previous filing, the need for financing, remains critical, underscored by the auditor's going concern statement, indicating continued financial vulnerability despite the commercial launch.

Filing Stats: 4,491 words · 18 min read · ~15 pages · Grade level 14.3 · Accepted 2025-12-23 16:21:08

Key Financial Figures

Filing Documents

Business

Business 1 Item 1A. Risk Factors 33 Item 1B. Unresolved Staff Comments 66 Item 1C. Cybersecurity 66 Item 2.

Properties

Properties 66 Item 3. Legal Proceedings 66 Item 4. Mine Safety Disclosures 66 PART II 67 Item 5. Market for Registrant's Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities 67 Item 6. [Reserved] 67 Item 7. Management's Discussion and Analysis of Financial Condition and Results of Operations 68 Item 7A. Quantitative and Qualitative Disclosures About Market Risk 76 Item 8. Financial 76 Item 9. Changes in and Disagreements With Accountants on Accounting and Financial Disclosure 76 Item 9A. Controls and Procedures 77 Item 9B. Other Information 77 Item 9C. Disclosure Regarding Foreign Jurisdictions that Prevent Inspections 77 PART III 78 Item 10. Directors, Executive Officers and Corporate Governance 78 Item 11. Executive Compensation 78 Item 12. Security 78 Item 13. Certain Relationships and Related Transactions, and Director Independence 78 Item 14. Principal Accountant Fees and Services 78 PART IV 79 Item 15. Exhibits and Financial Statement Schedules 79 Item 16. Form 10-K Summary 82

Signatures

Signatures 83 NOTES In this annual report on Form 10-K, and unless the context otherwise requires, the "Company," "we," "us" and "our" refer to Citius Pharmaceuticals, Inc. and its wholly-owned subsidiaries Citius Pharmaceuticals, LLC and Leonard-Meron Biosciences, Inc., and its majority-owned subsidiaries, Citius Oncology, Inc. (Nasdaq: CTOR) ("Citius Oncology") and NoveCite, Inc., taken as a whole. Mino-Lok and LYMPHIR TM (denileukin diftitox) are our registered trademarks. All other trade names, trademarks and service marks appearing in this annual report are the property of their respective owners. We have assumed that the reader understands that all such terms are source-indicating. Accordingly, such terms, when first mentioned in this report, appear with the trade name, trademark or service mark notice and then throughout the remainder of this report without trade name, trademark or service mark notices for convenience only and should not be construed as being used in a descriptive or generic sense.

FORWARD-LOOKING STATEMENTS

FORWARD-LOOKING STATEMENTS This Annual Report on Form 10-K contains "forward-looking plans, strategies, predictions, or any other statements relating to our future activities or other future events or conditions. These These statements are not guarantees of future performance and involve risks, uncertainties and assumptions that are difficult to predict. Therefore, actual outcomes and results may, and are likely to, differ materially from what is expressed or forecasted in the forward-looking Factors," and Item 7 - "Management's Discussion and Analysis of Financial Condition and Results of Operations" in this report and in other documents which we file with the Securities and Exchange Commission ("SEC"). In addition, such our independent registered public accounting firm's report includes an explanatory paragraph stating that there is substantial doubt about our ability to continue as a going concern; our need for substantial additional funds and its ability to raise those funds; our ongoing evaluation of strategic alternatives; the ability of Citius Oncology to commercialize LYMPHIR, including covering the costs of licensing payments, product manufacturing and other third-party goods and services; our ability to recognize the anticipated benefits of the August 2024 reverse merger whereby Citius Oncology became a standalone publicly-traded company and our majority-owned subsidiary (the "Merger"), which may not be realized fully, if at all, or may take longer to realize than expected; o

Business

Item 1. Business Overview Citius Pharmaceuticals, Inc., headquartered in Cranford, New Jersey, is a biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products, with a focus on oncology, anti-infectives in adjunct cancer care and unique prescription products. Our goal generally is to achieve leading market positions by providing therapeutic products that address unmet medical needs yet have a lower development risk than usually is associated with new chemical entities. New formulations of previously approved drugs with substantial existing safety and efficacy data are a core focus. We seek to reduce development and clinical risks associated with drug development, yet still focus on innovative applications. Our strategy centers on products that have intellectual property and regulatory exclusivity protection, while providing competitive advantages over other existing therapeutic approaches. In December 2025, we became a commercial company with the launch of LYMPHIR by our majority owned subsidiary Citius Oncology. We also have late-stage product candidates in development. Since its inception, the Company has devoted substantially all of its efforts to business planning, acquiring our proprietary technology, research and development, recruiting management and technical staff, and raising capital. We are developing three proprietary products Mino-Lok, an antibiotic lock solution used to treat patients with catheter-related bloodstream infections by salvaging the infected catheter; Halo-Lido, a corticosteroid-lidocaine topical formulation that is intended to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids; and NoveCite, a mesenchymal stem cell therapy for the treatment of ARDS. Citius Oncology achieved the approval from the FDA for LYMPHIR, in-licensed by Citius Pharma in September 2021 (now owned by Citius Oncology), an engineered IL-2 diphtheria toxin fusion protein,

View Full Filing

View this 10-K filing on SEC EDGAR

View on Read The Filing